Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt to Equity (2016 - 2021)

Lineage Cell Therapeutics' Debt to Equity history spans 6 years, with the latest figure at $0.0 for Q1 2021.

  • For Q1 2021, Debt to Equity changed N/A year-over-year to $0.0; the TTM value through Mar 2021 reached $0.0, changed N/A, while the annual FY2020 figure was $0.01, N/A changed from the prior year.
  • Debt to Equity reached $0.0 in Q1 2021 per LCTX's latest filing, down from $0.01 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.01 in Q3 2020 to a low of $0.0 in Q4 2017.
  • Average Debt to Equity over 3 years is $0.0, with a median of $0.0 recorded in 2021.
  • The largest YoY upside for Debt to Equity was 73.27% in 2017 against a maximum downside of 88.08% in 2017.
  • A 3-year view of Debt to Equity shows it stood at $0.0 in 2017, then soared by 4917.24% to $0.01 in 2020, then decreased by 18.39% to $0.0 in 2021.
  • Per Business Quant, the three most recent readings for LCTX's Debt to Equity are $0.0 (Q1 2021), $0.01 (Q4 2020), and $0.01 (Q3 2020).